Article

Alphaeon enters agreement with PhysIOL for trifocal lens technology

Alphaeon Corp. announced it has entered into a definitive agreement with PhysIOL SA, of Belgium, to jointly develop and commercialize an exclusive Alphaeon-branded trifocal lens technology.

Las Vegas-Alphaeon Corp. announced it has entered into a definitive agreement with PhysIOL SA, of Belgium, to jointly develop and commercialize an exclusive Alphaeon-branded trifocal lens technology.

Specific terms of the agreement were not disclosed in a statement from the company.

PhysIOL’s research and development has produced a range of innovative products, designed in partnership with ophthalmic surgeons, as well as specialized research centers and universities. This partnership enables Alphaeon to bring PhysIOL trifocal lens technology to the United States for the first time, according to the statement.

 

“Alphaeon’s development and regulatory capabilities combined with our expertise in design and manufacturing of trifocal IOL technologies make this an ideal partnership,” said Marc Nolet, chief executive officer (CEO) of PhysIOL. “Additionally, we’re excited to leverage Alphaeon’s market access through its highly innovative ShoutMD proprietary social commerce platform.”

“We are very pleased to collaborate with PhysIOL,” said Robert E. Grant, CEO of Alphaeon. “With this new agreement, we will seek to advance the premium category for patients looking for excellent visual acuity outcomes across their range of vision, at near, mid, and distance.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.